Survival outcomes according to adjuvant chemotherapy duration and oxaliplatin use in patients aged 70 years and older with stage II–III colon cancer
Turkish Journal of Clinics and Laboratory · 14.03.2026 · (1)
DOI: 10.18663/tjcl.1861167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Clinics and Laboratory, online erschienen am 14.03.2026. Verfasst von Ömer Acar und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aim
The optimal balance between treatment duration and regimen selection in older patients with stage II–III colon cancer remains uncertain in real-world practice. This study aimed to evaluate survival outcomes according to adjuvant chemotherapy duration and oxaliplatin use in older patients with stage II–III colon cancer.Material and Methods: This retrospective cohort study included patients aged ≥70 years with stage II–III colon adenocarcinoma who underwent curative-intent surgery and received adjuvant chemotherapy between 2015 and 2023. Patients were grouped according to adjuvant chemotherapy regimen (oxaliplatin-based vs non-oxaliplatin) and treatment duration. Overall survival (OS) and disease-free survival (DFS) were analyzed using the Kaplan–Meier method. Factors associated with survival outcomes were evaluated using Cox proportional hazards regression, and multivariable logistic regression analyses were additionally performed for all-cause mortality and recurrence.
Results
A total of 65 patients were included, of whom 35 received oxaliplatin-based regimens. Patients treated with oxaliplatin were younger and more frequently had stage III disease. In multivariable analysis, age >75 years (OR 3.45, 95% CI 1.16–10.21; p = 0.026) and adjuvant chemotherapy duration
Zitieren
APA
Acar, Ö., Türkmen, E., Şahbazlar, M., Ekinci, F., & Erdoğan, A. P. (2026). Survival outcomes according to adjuvant chemotherapy duration and oxaliplatin use in patients aged 70 years and older with stage II–III colon cancer. Turkish Journal of Clinics and Laboratory. https://doi.org/10.18663/tjcl.1861167
Vancouver
Acar Ö, Türkmen E, Şahbazlar M, Ekinci F, Erdoğan AP. Survival outcomes according to adjuvant chemotherapy duration and oxaliplatin use in patients aged 70 years and older with stage II–III colon cancer. Turkish Journal of Clinics and Laboratory. 2026. doi:10.18663/tjcl.1861167
BibTeX
@article{Acar2026,
author = {Acar, Ömer and Türkmen, Emine and Şahbazlar, Mustafa and Ekinci, Ferhat and Erdoğan, Atike Pinar},
title = {Survival outcomes according to adjuvant chemotherapy duration and oxaliplatin use in patients aged 70 years and older with stage II–III colon cancer},
journal = {Turkish Journal of Clinics and Laboratory},
year = {2026},
number = {1},
doi = {10.18663/tjcl.1861167}
}
EUVIMED